Clinical trials: Multiple Sclerosis, Relapsing-remitting
Multiple Sclerosis
Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS
Gilenya (fingolimod) is approved for multiple sclerosis. However, it is unclear of its clinical effect in the Hispanics with MS given that clinical studies had limited representation of this population.
- Trial name
- NCT01592097
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- University of Southern California
Relapsing-Remitting Multiple Sclerosis
A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)
The purpose of this study is to test MK0812 on disease activity in patients with relapsing-remitting MS. Disease modifying activity will be assessed by measurement of brain lesions via MRI brain scans and an open label extension…
- Trial name
- NCT00239655
- Testing
- MK0812
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Sclerosis, Relapsing-Remitting
A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis
The purpose of this study is to assess the safety and the preliminary efficacy of a single infusion of stimulated autologous CD4+ T cells in patients with Relapsing-Remitting Multiple Sclerosis.
- Trial name
- SCLEROLYM (NCT02427776)
- Testing
- Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope
- Where
- 3 sites in Belgium
- Volunteers
- 2 people
- Sponsor
- Imcyse SA
Multiple Sclerosis, Relapsing-Remitting
Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012
The primary objective(s) of the study are to assess the BG00012 (dimethyl fumarate) treatment effect on cognition over 2 year period in RRMS patients.
- Trial name
- StarTec (NCT02579681)
- Testing
- dimethyl fumarate
- Where
- 18 sites in Italy
- Volunteers
- 221 people
- Sponsor
- Biogen
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis
The purpose of this study is to better understand the mechanism of action (MoA) of cladribine tablets by exploring the effect on central nervous system (CNS) and blood biomarkers relevant in the relapsing forms of multiple…
- Trial name
- CLOCK-MS (NCT03963375)
- Testing
- Cladribine
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Gregory Wu
Multiple Sclerosis, Multiple Sclerosis-Relapsing-Remitting
Intermittent Hypoxia in Persons With Multiple Sclerosis
This study aims to understand the mechanisms of a novel intervention involving breathing short durations of low levels of oxygen for persons with multiple sclerosis (MS).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis-Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT06276634
- Testing
- Acute Intermittent Hypoxia
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Shirley Ryan AbilityLab
Relapsing-remitting Multiple Sclerosis
Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS
A 6 months prospective, randomized, multicenter, controlled, parallel-group, open-label study in RRMS patients to assess the impact of an individualized patient support program (PSP) on treatment satisfaction and to evaluate…
- Trial name
- STAY (NCT01709812)
- Testing
- individualized patient support program, Standard care
- Sponsor
- Novartis Pharmaceuticals
Cognition, Brain Volume Loss
Effect of Fingolimod on Neurodegeneration
This was a 24-month, open-label, multicenter study with a single treatment arm design. Primary objective of this study was: -To investigate the effects of Fingolimod on cognitive performance in highly active relapsing remitting…
- Trial name
- NCT02575365
- Testing
- 0,5 mg Fingolimod
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Relapsing Remitting Multiple Sclerosis
Atorvastatin in Relapsing-Remitting Multiple Sclerosis
A phase II open-label baseline-to-treatment trial was designed to evaluate the safety, tolerability and efficacy of orally administered atorvastatin in patients with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT00616187
- Testing
- interferon beta treatment to add-on atorvastatin treatment, untreated to atorvastatin treatment
- Volunteers
- 41 people
- Sponsor
- Charite University, Berlin, Germany
Multiple Sclerosis, Relapsing-remitting
Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) Study
To examine short- and long-term value of appearance of new active lesions in predicting extent of cortical and subcortical deep gray matter (SDGM) atrophy over 5 years in ASA (Avonex- Steroid-Azathioprine)study.
- Trial name
- ASA (NCT01628315)
- Testing
- MRI
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- University at Buffalo
Multiple Sclerosis, Relapsing-Remitting, Clinically Isolated Syndrome
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
The purpose of this study is to further evaluate the safety and efficacy of Tovaxin in the treatment of relapsing forms of multiple sclerosis.
- Trial name
- OLTERMS (NCT00595920)
- Testing
- Tovaxin
- Where
- 27 sites in United States
- Volunteers
- 116 people
- Sponsor
- Opexa Therapeutics, Inc.
Multiple Sclerosis, Relapsing-Remitting
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT06408259
- Testing
- Ozanimod, Fingolimod
- Where
- 33 sites in United States, Australia and 9 more
- Volunteers
- 194 people
- Sponsor
- Bristol-Myers Squibb
Multiple Sclerosis, Relapsing-Remitting
Healthy Volunteer Study Using 3 Different Formulations of Firategrast
This study will investigate how 3 types of drug formulations are absorbed by the body. This study is termed 'open-label', which means volunteers will be aware of which treatment they are receiving.
- Trial name
- NCT01416363
- Testing
- Firategrast immediate release tablet, Firategrast modified release tablet, Firategrast gastro-retentive solution
- Where
- Australia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis, MS, Multiple Sclerosis
Transcranial Direct Current Stimulation for Fatigue, Mood, and Cognition in Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, inflammatory and disabling disease of the Cnetral Nervous System characterized by relapsing and / or progressive somatosensory, motor and vestibular clinical manifestations.
- Conditions
- Multiple Sclerosis, MS, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive
- Trial name
- NCT07680738
- Testing
- Transcranial Direct Current Stimulation
- Where
- Mexico
- Volunteers
- 38 people
- Sponsor
- Universidad de Almeria
Relapsing-Remitting Multiple Sclerosis
PK and PD Study of Natalizumab in Pediatric Subjects With RRMS
The primary objective of the study is to determine the pharmacokinetic (PK) profile of multiple doses of natalizumab in pediatric subjects with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT01884935
- Testing
- Natalizumab
- Where
- 5 sites in Italy
- Volunteers
- 13 people
- Sponsor
- Biogen
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
Extracorporeal Shock Wave Therapy in Enhancing Sensitivity and Postural Stability in Multiple Sclerosis
This randomized controlled trial aimed to investigate the efficacy of Extracorporeal Shock Wave Therapy (ESWT) on plantar somatosensory function, knee joint proprioception, and spatiotemporal gait parameters in individuals…
- Conditions
- Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Sensorimotor Gait Disorder
- Trial name
- NCT07514104
- Testing
- Extracorporeal Shock Wave Therapy (ESWT)
- Where
- Turkey (Türkiye)
- Volunteers
- 54 people
- Sponsor
- Furkan Bilek
All Multiple Sclerosis Patients
Fatigue Treatment Using Provigil
To determine whether therapy with Modafinal(Provigil) is safe and effective in fatigue in MS Patients
- Trial name
- NCT00220506
- Testing
- Provigil
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Sheba Medical Center
Relapsing Remitting Multiple Sclerosis
Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.
This is a 24-week phase 1b, randomized, double-blind, placebo-controlled, parallel-group, multicenter safety study comparing the tolerance profile of olesoxime (495 mg, od) when administered on top of Interferon beta in patients…
- Trial name
- MSREPAIR (NCT01808885)
- Testing
- olesoxime (TRO19622)
- Where
- 3 sites in France
- Volunteers
- 44 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Relapsing-Remitting
Identifying Immune Biomarkers of Disease and Disease Control in Autoimmune Neurological Disease Using Autologous Haematopoietic Stem Cell Transplantation
The underlying disease mechanisms which occur in patients with immune mediation neurological diseases, such as Multiple Sclerosis (MS), are incompletely understood.
- Trial name
- BIO-MS (NCT06195800)
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Relapsing-Remitting Multiple Sclerosis
Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
The primary objective of the study is to evaluate the impact of early treatment with Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) participants on their quality of life (QoL) as measured by Multiple Sclerosis Impact…
- Trial name
- COSTAN (NCT01706107)
- Where
- 11 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Biogen